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Abstract
Background: Hypalbuminemia is associated with numerous postoperative complications, so a perioperative
albumin substitution is often considered. The objective of SuperAdd is to investigate whether substitution of
human albumin, aiming to maintain a serum concentration > 30 g/l, can reduce postoperative complications in
normovolemic surgical patients in comparison with standard care.
Methods/design: SuperAdd is a single-center, prospective, randomized, outcome-assessor blinded, patient blinded
controlled trial. The primary outcome is the frequency of postoperative complications identified using the Postoperative
Morbidity Survey graded ≥ 2 according to the Clavien-Dindo Score. Adult patients at risk to develop hypalbuminemia, i.e.,
ASA III or IV or high-risk surgery, are recruited after written informed consent was obtained. The albumin concentration is
assessed before the induction of anesthesia and every 3 h until admission to the postanesthesia care unit. If albumin
concentrations drop below 30 g/l, patients are randomly allocated to the control or the treatment group. The study
intervention is a goal-directed human albumin substitution aimed at a concentration > 30 g/l during surgery and
postanesthesia care unit stay. The patients in the control group are treated according to standard clinical care.
Postoperative visits are to be performed on days 1, 3, 5, 8, and 15, as well as by telephone 6months after surgery.
Discussion: SuperAdd is the first clinical trial in a surgical population investigating the effect of a goal-directed albumin
substitution aiming at a serum level > 30 g/l. The nonrestrictive selection of patients guarantees that the patients without
albumin screening will most likely not develop hypalbuminemia, thus ensuring generalizability of the study results.
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Background
Postoperative complications contribute significantly to
morbidity and mortality. A recent analysis suggests that
postoperative mortality is the third leading cause of death,
with at least 4.2 million people worldwide dying within 30
days of surgery each year [1]. Accordingly, perioperative
research often focuses on prevention and early recognition
of postoperative complications. Hypalbuminemia warrants
special consideration due to its association with numerous
postoperative complications [2–4]. Hypalbuminemia can
preexist as a result of a poor preoperative nutritional sta-
tus, critical or chronic illness, an insufficient hepatic syn-
thesis [5], or can be acquired over the perioperative
course due to bleeding or capillary leakage [6].
As an integral component for homeostasis, perioperative
hypalbuminemia may promote postoperative complica-
tions. Albumin is the major binding and transporting pro-
tein of hormones, coagulation factors [7], and drugs.
Furthermore, albumin is a key determinant of oncotic
pressure in the vascular system [8], which is a prerequisite
for organ perfusion [9]. Therefore, it seems reasonable to
consider perioperative albumin substitution.
Aside from studies in intensive care patients [10–12], there
are only retrospective [13] or small prospective studies in the
perioperative setting, with conflicting results [14, 15] and lim-
ited significance. These studies were heterogeneous, analyz-
ing different indications, such as treatment of hypovolemia
or hypalbuminemia, different regimes of substitution, and
different outcome measures. Accordingly, the clinical ques-
tion as to whether perioperative albumin deficits should be
substituted in the perioperative setting cannot be answered
based on the published knowledge. We hypothesize that a
goal-directed albumin substitution is likely to be beneficial in
surgical patients with an acute loss of albumin.
The aim of the SuperAdd trial is to investigate whether
substitution of human albumin, aiming to maintain a serum
concentration > 30 g/l, is able to reduce postoperative com-




The SuperAdd trial is a single-center, prospective, random-
ized, outcome-assessor blinded, controlled trial performed in
a university hospital (Technical University of Munich, Klini-
kum rechts der Isar, Germany). The SuperAdd workflow is
provided in Fig. 1 and the SPIRIT Checklist as
Additional file 1.
Eligibility criteria
Patients scheduled for surgery in the departments of vas-
cular, abdominal, trauma, or orthopedic surgery are re-
cruited during the preoperative anesthesia visit.
Inclusion criteria include: (1) ≥ 18 years old, (2) written
informed consent, and (3) being at risk for the develop-
ment of hypalbuminemia, which was assumed for either
(3a) American Society of Anesthesiologists status III or
IV or (3b) high-risk surgery such as esophagectomy, liver
surgery, pancreatic surgery, open aortic surgery, open
leg revascularization, thrombectomy, limb amputation,
or revision of knee and hip arthroplasty.
Exclusion criteria are (1) emergency surgery, (2) severe
liver cirrhosis (Child-Pugh score C), (3) terminal kidney
failure requiring dialysis, (4) patients previously random-
ized to this trial or participation in another clinical trial
in the past three months, in accordance with German
medication laws, (5) patients who have a legal guardian
for medical decisions, (6) patients with a history of al-
lergy to albumin or auxiliary substances, (7) pregnant
women, (8) breastfeeding women, and (9) patients with a
body mass index > 35 kg/m2.
Interventions
The study intervention is a goal-directed albumin substi-
tution with boluses of 20 g human albumin given in 100-
ml bottles (Human Albumin 20% Behring™, CSL Behring,
Marburg, Germany) to reach albumin serum concentra-
tions ≥ 30 g/l throughout surgery and during the postoper-
ative anesthesia care unit (PACU) stay. Albumin solutions
will be infused in whole bottles. The number of bottles is
related to the difference between the actual and
target albumin concentration and the patient’s body
weight:
number of albumin bottles
¼ 30 g=l − albumin concentrationð Þ  bodyweight
 4 l=kg2
The effect is controlled and if necessary escalated.
According to standard clinical care, patients of the
control group will be not treated with albumin. If
hemodynamic instability persists despite normovolemia,
exceptions will be allowed, but the target will remain a
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serum albumin concentration of 20 g/l. The maximum
allowed number of albumin bottles is accordingly:
number of albumin bottles
¼ 20 g=l − albumin concentrationð Þ  bodyweight
 4 l=kg2:
Blinding (masking)
The intervention is performed by the unblinded anesthe-
siologists in the operation room and PACU. Patients re-
main blinded, and the outcome is assessed by blinded
physicians of the corresponding surgical department,
assisted by blinded study staff. Neither the albumin con-
centration nor the infusion is documented on the la-
boratory report, the anesthesia report, or the PACU
report. Statistical analyses as well as the interim analyses
are undertaken independently by statisticians blinded to
the treatment group allocation.
Anesthesia and fluid resuscitation
All patients receive anesthesia according to the hospital’s
standard procedures for patients with ASA 3 or 4 status
or high-risk surgery [19]. In particular, fluid resuscitation
guarantees normovolemia using balanced crystalloids
and gelatine solutions, in accordance with the German
Guidelines for intraoperative fluid substitution [20].
Major bleedings and coagulation disorders are treated
according to the German Guidelines for therapy with
blood compounds and plasma derivatives [21]. Excep-
tions include the treatment with fresh frozen plasma and
albumin preparations. While albumin is only allowed ac-
cording to the study protocol, the infusion of fresh
frozen plasma is prohibited due to its albumin content,
and its usage represents a major protocol violation.
Outcomes measures
The primary outcome measure is the occurrence and se-
verity of postoperative complications, identified using
the Postoperative Morbidity Survey (POMS) assessed on
postoperative days 3, 5, 8, and 15 and at hospital dis-
charge, and graded according to the Clavien-Dindo
Score. In brief, the POMS counts the number of do-
mains, in which a complication leading to a prolongation
of hospitalization occurs. The nine screened domains
are pulmonary, infectious, cardiovascular, neurological,
renal, gastrointestinal, wound, pain, and hematological
morbidities [17]. Since the POMS does not grade the se-
verity of each complication, we additionally grade each
complication using the Clavien and Dindo scale (Table 1)
[18]. The primary endpoint is the frequency of patients
with at least one clinically relevant postoperative compli-
cation, graded as Clavien-Dindo Score ≥ 2, on at least
one postoperative day until hospital discharge.
Secondary outcome variables are the subjective quality
of recovery, in-hospital and 180-day mortality, length of
stay in the PACU, intensive care unit and hospital, inci-
dence of complications and the respective surrogate var-
iables in the nine POMS domains (e.g., acute kidney
injury, pulmonary congestion, myocardial injury after
noncardiac surgery, perioperative catecholamine require-
ments, hypotension, infusion, and transfusion), and the
efficiency of the albumin substitution.
The quality of recovery is assessed using the Quality of
Recovery-9 (QoR-9) Questionnaire preoperatively and
postoperatively on days 1, 3, and 180. The QoR-9 Ques-
tionnaire is a nine-item scale to determine subjective
Fig. 1 Schedule of enrolment, interventions, and assessments according to the SPIRIT guidelines [16]. PACU, postanesthesia care unit. The
Postoperative Morbidity Survey (POMS) screens nine domains (pulmonary, infectious, cardiovascular, neurological, renal, gastrointestinal, wound,
pain, and hematological morbidities) [17]. The severity of the complication is graded according to the Clavien-Dindo Score (Table 1) [18]
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recovery after surgery (Table 2) in its German version
[22, 23]. Total QoR-9 scores range from 0 to 18, with
higher scores indicating better recovery.
Albumin in serum is measured photometrically on a
Cobas 8000 c702 analyzer using the original reagent kit
(Roche Diagnostics, Mannheim, Germany). High-
sensitive cardiac troponin T in serum is measured using
a sandwich electrochemiluminescent immunoassay on a
Cobas 8000 e602 analyzer and original reagent kits
(Roche Diagnostics, Mannheim, Germany). Immature
platelets are measured using a fully automated analyzer
(Sysmex XE-5000, Sysmex, Kobe, Japan). The device
uses two fluorescent dyes containing polymethine and
oxazine, which penetrate the cell membrane staining the
RNA. Stained cells are then passed through a semicon-
ductor laser beam, allowing differentiation between im-
mature and mature platelets by plotting forward scatter
light (measuring cell volume) against fluorescence inten-
sity (representing RNA content) [24].
Participant timeline
Patients are screened for eligibility, informed about the
study, and asked for their consent during the preoperative
anesthesia evaluation by any qualified anesthesiologist on
duty. After arrival in the operation theater, albumin assess-
ment starts as the second step of the screening process. For
this purpose, albumin concentration is determined before
the induction of anesthesia and at least every 3 h until ad-
mission to PACU. If the albumin concentration does not
drop below 30 g/l, the patient will not be recruited. If the al-
bumin concentration drops below 30 g/l, the patient is to
be randomly allocated to the intervention or the control
treatment. The randomized patients’ albumin concentra-
tion is to be assessed again every 3 h, as well as after each
albumin infusion, until the intervention period ends with
discharge from the PACU. Postoperative visits are to be
performed on days 1, 3, 5, 8, and 15, unless the patient is
previously discharged from the hospital. The patient will be
contacted via phone 6 months after surgery.
Allocation
The randomization list was generated by SJS using a 1:1
ratio and random blocks of 4, 8, or 16 using www.
randomization.com. There was no stratification. The
randomization list was generated using the same tech-
nique after the interim analysis. The list was transferred to
an external contractor, which established a password-
restricted internet platform on a university server in a vali-
dated process to ensure the correct order. Each member
of the randomization team (BJ, KF, MB, SJS, or SS) holds
an individualized login enabling randomization. The
randomization team is available 24/7 via the study tele-
phone. If a patient is to be randomized, the treating
anesthesiologist calls the study telephone and provides the
albumin level (to ensure that randomization is possible)
and a 7-digit case identification number of the hospital
record system. The randomization team checks if the
signed informed consent is documented and performs the
randomization in the online system. The allocation “inter-
vention” or “standard care” is then reported back to the
anesthesiologist via the phone. The anesthesiologist then
documents the randomization number in the electronic
anesthesia report. In case of technical issues with the on-
line randomization, closed envelopes with printed
randomization numbers are available in a locked safe at
the intensive care unit of the department, accessible 24/7
through the head nurse of the ICU if necessary. The
Table 1 Definition of the Clavien-Dindo Score [18]
Grades Definition
Grade I Any deviation from the normal postoperative course
without the need for pharmacological treatment or
surgical, endoscopic, and radiological interventions.
Allowed therapeutic regimens are drugs as antiemetics,
antipyretics, analgesics, diuretics, and electrolytes and
physiotherapy. This grade also includes wound infections
opened at the bedside.
Grade II Requiring pharmacological treatment with drugs other
than such allowed for grade I complications.
Blood transfusions and total parenteral nutrition are also
included.
Grade III Requiring surgical, endoscopic, or radiological intervention.
Grade III-a Intervention not under general anesthesia.
Grade III-b Intervention under general anesthesia.
Grade IV Life-threatening complication (including CNS
complications) requiring IC/ICU management.
Grade IV-a Single organ dysfunction (including dialysis).
Grade IV-b Multi-organ dysfunction.
Grade V Death of a patient.
Table 2 Quality of Recovery (QoR-9) Questionnaire. Each
question can be quoted with 0, 1, or 2 according to the level of
agreement. The total score is the sum of all responses. As the
last three questions are asked inversely, the scoring scheme is
to be inverted
QoR-9 questions
Had a feeling of general well-being.
Had support from others (especially doctors and nurses).
Been able to understand instructions and advice. Not being confused.
Been able to look after personal toilet and hygiene unaided.
Been able to pass urine and having no trouble with bowel function.
Been able to breathe easily.
Been free from headache, backache, or muscle pains.
Been free from nausea, dry retching, or vomiting.
Been free from experiencing severe pain or constant moderate pain.
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anesthesiologist can open the envelope and find the re-
spective group assignment.
Recruitment
The stepwise inclusion process is recognized a priori as
a bottleneck for recruitment. Therefore, an emphasis
was placed in defining a clear sequence of measures and
responsibilities. First, we explicitly defined the popula-
tion to be screened; the patients at surgical risk of losing
albumin, specified as a list of high-risk surgical proce-
dures or patients at risk for slow albumin synthesis, spe-
cified using the ASA risk score ≥ 3. Accordingly, we
trained all anesthesiologists of the department in the
correct use of the ASA risk score and the list of high-
risk surgical procedures at least every 4 months. Second,
we recruit patients of specified surgical departments op-
erating in the same operation theater with 10 operation
rooms. The attending anesthesiologists are trained to
guarantee sampling of blood according to the given
timelines, to ensure their appropriate labeling, to blind
the surgical staff, and to prioritize albumin analysis in
the department of clinical chemistry. Third, the anesthe-
siologists are quickly informed about the albumin con-
centration using telephone- and IT-based information
pathways. Finally, the investigational product is prepared
to be rapidly delivered by the transfusion department.
Strategies to improve adherence to intervention
protocols
We provide regular lectures for the participating depart-
ments. The randomization team can be contacted at any
time to assist the anesthesiologists in charge with the re-
quirements of the study protocol, in particular with the
intervention. Furthermore, the study protocol is published
in our in-house network, which is available on the moni-
tor of the patient data management system. Finally, each
anesthesiologist is equipped with a pocket card including
major information about the study-related requirements.
Criteria for discontinuing or modifying allocated
interventions
Allergic reactions against the albumin preparation must
be reported as a severe adverse event. If this is sus-
pected, the trial medication is to be stopped immedi-
ately. Protocol violations, such as infusion of fresh
frozen plasma or albumin preparations outside the study
intervention, do not lead to termination of participation
in the study.
Sample size
The frequency of complications graded as Clavien-
Dindo Score > 2 in surgical patients with preoperative
hypalbuminemia has been reported as 52%, compared to
23% in patients with normal albumin concentration,
according to an observational study in patients with ovar-
ian cancer [3]. We assumed a clinically relevant treatment
effect if albumin substitution could halve the absolute risk
difference between patients with hypalbuminemia and
normal albumin, i.e., an absolute risk reduction of 14% or
a relative risk reduction of approximately 25%. Since a
general surgical population was likely to have a different
risk of complications related to hypalbuminemia, an in-
terim analysis was planned after 100 patients, so as to bet-
ter estimate the risk of complications in the study
population and recalculate the sample size using a 25%
relative risk reduction.
After inclusion of 100 patients, an independent statisti-
cian compared the two treatment groups for the inci-
dence of any postoperative complications graded as
Clavien-Dindo ≥2 and > 2, using a two-sided χ2 test for
independent samples. Had the difference between
groups reached a significance level of 0.002, the study
would have been terminated. Since the incidences of
complications graded as Clavien-Dindo ≥ 2 after 100 pa-
tients were 82% vs. 84% (p = 0.79) and those scored
Clavien-Dindo > 2 were 34% vs. 36% (p = 0.83), the study
must be continued. Hence, the 95% confidence interval
of the relative risk for complications graded Clavien-
Dindo ≥ 2 includes the postulated 25% relative risk re-
duction (0.87 [0.37–2.03]), the interim analysis also
failed to show a missing treatment effect, which would
also terminate the study. Based on incidences of the in-
terim analysis, a significance level of 0.048, and a power of
80%, a sample size of 4408 patients would be required to
prove significance. In fact, the study was limited to 300 pa-
tients per group, according to the prerequisite given by
the responsible authority, the Paul-Ehrlich-Institut. Based
on the limited number of 2 × 300 patients, the frequencies
of complication of 82% and 84% and a significance level of
0.048, the power would be 50%.
Data collection methods
Database management is delegated to the Munich Study
Center, Munich, Germany (MSZ). First, data management
and data verification plans were generated, followed by
the creation of a validated study database using the plat-
form EDC-System Macro (Elsevier, London, UK). Data
electronically available in the anesthesia protocol is trans-
ferred into the database using a validated process. Screen-
ing, medical history, and PACU data is entered manually
into the database by unblinded study staff. Blinded out-
come data is entered in specified study iPads (Apple Inc.,
Cupertino, CA, USA) using FileMaker 16 Go (Claris Inter-
national Inc. c/o Apple, Santa Clara, CA, USA) with a vali-
dated transfer process into the study database.
There is a prespecified monitor plan in place, includ-
ing five on-site visits and remote monitoring every
6 weeks. Execution is delegated to the MSZ. On-site
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monitoring consists of source data verification and
source data review, while data review will be performed
remotely. The frequency of visits can be adapted in case
of significant recruitment delays or other issues arise.
All study database users receive required training ap-
plicable to their role in the conduction of the trial. The
completion of this training is tracked and attested by an
instructor, who also review and verify the appropriate
conduction of the trial and adherence to data accuracy
and security goals.
Data management
All data entered into the database is reviewed. Data clean-
ing is planned in three rounds to resolve discrepancies,
search for missing data, and declare them as not available
should no solutions be found. Furthermore, protocol vio-
lations are identified and classified. Withdrawal of the
consent before anesthesia, i.e., before recruitment and
intervention, is reported in the CONSORT diagram only.
Withdrawal of the consent after intervention is also re-
ported, but will not affect the study related analysis of the
already collected data, as well as all safety-related events
even after withdrawal. Loss of contact information may re-
sult in loss of follow-up information, which can be re-
duced through inquiries to the respective municipal
registration offices.
The database will be locked and exported for statistical
analysis. At this stage, permission for access to the data-
base will be revoked for all investigators, and the data-
base will be archived.
Missing information on the outcome variables, irre-
spective of the reason, results in the exclusion of a pa-
tient. If more than 5% of patients are excluded from the
primary analysis, the study aim cannot be reached.
Statistical methods
The statistical analysis plan is described in the study
protocol. This version and its amendments are published
at http://www.superadd.de, and any further updates will
be made available there. After closing of the database,
no changes to the analysis plan will be allowed.
Scaled variables will be presented, depending on their
distribution, as mean and standard deviation or median
and interquartile range. Categorical variables will be rep-
resented as numbers and frequencies.
Statistical analyses will be performed for all given out-
comes, irrespectively of any protocol violation (intension-
to-treat analysis). In case of major protocol violations or
discontinuation due to treatment-specific complications,
an exploratory patient-per-protocol analysis will be per-
formed, excluding the respective patients.
The primary endpoint is the incidence of any postop-
erative complications graded as Clavien-Dindo ≥ 2. The
two treatment groups will be compared using a two-
sided χ2 test for independent samples regarding the inci-
dence of any postoperative complication. The results will
be presented as absolute risk reduction based on the
Mantel-Haenszel risk differences and its improved confi-
dence interval estimate [25]. Sub-groups analyses and ad-
justments will be included for risk groups according to
ASA status, preoperatively existing vs. intraoperatively ac-
quired hypalbuminemia, and varying surgical interven-
tions. Exploratory comparisons will be performed of each
component of the Clavien-Dindo, as well as each domain
of the POMS. Scaled surrogate variables of fluid therapy,
such as creatinine concentration, vasopressor infusion
rates, or need for supplementary oxygen during PACU,
will be compared with either t tests or Mann-Whitney U
tests, according to the distribution of the variable.
Statistical significance will be assumed at an alpha
level of 0.05. Statistical analyses will be conducted using
Statistical Package for the Social Sciences 26.0 (IBM
SPSS Statistics, Chicago, IL, USA).
Sub-studies
We expect that the albumin concentration of approxi-
mately 20% of the screened patients will drop below 30 g/l.
We will also analyze the serum samples of the remaining
80% (when screening for albumin) and will evaluate their
primary and secondary outcomes. These data will be col-
lected prospectively to allow secondary and exploratory
analyses. All collected serum samples will be analyzed for
immature platelets and hypersensitive troponin T concen-
trations. Planned sub-studies will evaluate the predictive
value of these biomarkers on postoperative complications
[26, 27]. Furthermore, we will evaluate whether postopera-
tive complications can be detected earlier using the QoR-9
instrument repetitively in this population [28].
Discussion
SuperAdd is the first clinical trial to investigate the effect
of a goal-directed albumin substitution in a surgical
population. Although hypalbuminemia is associated with
an increased risk of postoperative complications, the
substitution of the deficit is controversial due to the
large number of clinical conditions causing hypalbumi-
nemia and the diversity of treatment protocols. For in-
stance, albumin substitution in intensive care patients
with low albumin concentrations could not improve out-
comes, although more stable hemodynamic conditions
were reported [10–12]. Likewise, prophylactic albumin
substitution for 3 days in surgical patients could not re-
duce postoperative complications [15]. However, the
study could not even prove any surrogate effect of the
treatment. The daily substitution was 20 g albumin,
which was so meager that the concentrations continued
to drop in the 64 treated patients (22.5 ± 4.8 g/l)
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compared to the 63 control patients (21.9 ± 4.5 g/l), far
from enough to show any outcome effects.
Haynes and colleagues analyzed 79 randomized clin-
ical trials about albumin substitution in 2003 [29]. Their
metanalyses included 9 studies between 1948 and 1997,
in which hypalbuminemia indicated albumin substitu-
tion, whereas only one took place in a surgical setting.
Nevertheless, the metanalysis reported a consistent
dose-dependency and suggested a clinical benefit when
the attained albumin concentration exceeded 30 g/l. Re-
cently, the dose-dependency of the effect of albumin
substitution was confirmed in cardiac surgical patients.
Administration of albumin immediately prior to surgery,
aiming to increase the albumin level above 40 g/l, was
shown to reduce the risk of acute kidney injury after off-
pump coronary artery bypass surgery [14].
The primary outcome for this trial will be the fre-
quency of postoperative complications. We selected the
Clavien-Dindo Score [18] in combination with the
POMS [17], which has been announced by the COM-
PAC group as the best choice to measure organ failure
and survival in the context of the initiative to define
Standardised Endpoints in Perioperative Medicine (StEP)
[30]. While the Clavien-Dindo Score allows grading of
postoperative complications, the POMS systematically
addresses which organ system out of nine relevant do-
mains is affected, as well as at which time after surgery
it first develops. The combination of both instruments
will allow us to properly characterize the complications
and to understand how long the treatment effect can be
seen. Furthermore, exploratory analyses using each do-
main as an independent endpoint may allow for the
characterization of benefits or harms of the intervention
in each of the specified organ systems. For instance, fluid
may reduce acute kidney injury while increasing the risk
of lung edema.
A major limitation of the study design is the sample size
calculation. The prevalence of postoperative complications
is given, but not in combination with hypalbuminemia in
a general surgical population. Therefore, we performed an
interim analysis to better estimate the incidence of com-
plications and to get a figure of potential treatment differ-
ences. After 100 patients, the differences were so small
that approximately 9000 patients would be required for
the study and an expected number-needed-to-treat of 50
[28–232]. The study cohort size to answer the research
question was restricted a priori by the regulatory authority
to a maximum of 600 patients. In fact, we agree that if
there is no beneficial effect of albumin substitution in the
cohort of 600 patients with a high risk of complications
and given hypalbuminemia, the significant costs of the
substitution do not justify further consideration.
We are screening two specific cohorts with an ex-
pected high incidence of perioperative hypalbuminemia,
due to either an increased loss or a decreased synthesis
of albumin. The specified surgical procedures have a
transfusion risk > 20% in our hospital and patients with
an ASA risk score ≥ 3 are known to produce albumin at
a reduced rate [5]. With approximately 1200–1500 pa-
tients per year fulfilling the eligibility criteria at the oper-
ation units of the Klinikum rechts der Isar, we expect to
enroll the 600 patients during a recruitment period of
3 years. Accordingly, approximately 4000 patients will be
screened. The nonrestrictive selection guarantees that the
patients without albumin screening will most likely not
develop hypalbuminemia. Therefore, the high effort and
workload promises generalizability of the study results.
Trial status
The first patient was randomized on 25 June 2017. The
interim analysis was completed on 13 November 2018.
Recruitment will continue until the complete sample size
is achieved, which is expected to be in June 2020.
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